We expect HCG to deliver a healthy Ebitda CAGR of 19% over FY2018-20 and valuations are now reasonable at 13X FY2020e Ebitda. Upgrade to BUY with a target price of Rs 270 (versus Rs 290 earlier).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results